The Promising Role of Magnesium Taurate in Managing Hypertension

Abstract

Magnesium taurate may assist hypertensive individuals in reducing their blood pressure. The potential benefits of magnesium taurate in the treatment of hypertension and the general safety and ease of use of supplements provide support for this theory. The study aim To examine the effectiveness of magnesium taurate for management of hypertension and reduction levels of blood pressure in individuals with chronic hypertension. This study was included 164 individuals whose ages between (40-70) years. They were divided into two groups. The group I contain 82 healthy people that individuals without hypertension and group II contain 82 patients with hypertension. The 20 patients (10 men, 10 women) selected from group II were given a supplement known as magnesium taurate (500 mg per day) for one month (30 days) (depending on the FDA). Both groups were analyzed serum cortisol, magnesium and potassium as well as measure systolic and diastolic blood pressures for both groups daily and take reading weekly before and after given supplement nutrient. Study design: Two study design. First is cohort study design out-come of treatment is followed. Second is cross-sectional study. This study executed during the period from October 2023 to December 2024. Inclusion criteria: Hypertensive patient matching selection of study specification. Exclusion criteria: Hypothyroidism, hyperthyroidism - Cushing disease -Kidney disease - Heart disease - Women with poly cystic ovary syndrome (PCOS) - Pregnant women. Blood sample collection: Between 7.00 and 9.00 a.m., 10 ml of blood were drawn from all participants in the study via vein puncture, after overnight fasting (10-12) hour. A blood sample was left at room temperature 15 minute for clot formation and separated by centrifuge for 10 minutes at 3000rpm to collect serum and used to ass’s serum biochemical parameters. Tests principle: Serum cortisol measured by using cobas e601 (immunoassay analyzer), total duration of assay: 18 minutes. Serum magnesium measured by using cobas c501 (auto analyzer), Serum potassium measured by using electrolyte analyzer (SENSA CORE). Results: After adjusting for the age between the two groups, the cortisol level showed a significant decrease in the level of serum cortisol (316.30±59.6 nmol/dl) and a significant increase in the levels of serum magnesium (2.01±0.27 mg/dl) and serum potassium (4.31±0.25 mmol/l) after administrating magnesium taurate with a significant decrease in the blood pressure level (systolic blood pressure (130.00±7.20 mmHg) and diastolic blood pressure (80.30±3.64 mmHg)). In conclusion magnesium taurate supplementation not only restored hypertension-associated declines in serum magnesium and potassium, but also led to a significant reduction in serum cortisol levels. These enhancements imply a possible therapeutic benefit in the management of hypertension, especially when combined with a significant drop in blood pressure.